Loading stock data…
MNPR
$53.25+1.10 (+2.11%)
Market ClosedLast close May 1
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Monopar Therapeutics Inc. in the Healthcare sector is trading at $53.25. The stock is currently 49% below its 52-week high of $105.00, remaining 15.2% below its 200-day moving average. Technical signals show neutral RSI of 41 and bearish MACD signal, explaining why MNPR maintains its current current market pressure. The Whystock Score of 35/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 41) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$53.25
Potential Upside
5%
Whystock Fair Value$55.91
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus14 analysts
Mean target$112.79+111.8%
Range$100.00 – $130.00
Fundamentals
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNP...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$356.29M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.66
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-9.95%
Volume
Today's trading volume
78,461
Recent News
Institutional investors in Monopar Therapeutics Inc. (NASDAQ:MNPR) see US$66m decrease in market cap last week, although long-term gains have benefitted them.
Key Insights Institutions' substantial holdings in Monopar Therapeutics implies that they have significant influence...
Broadcom Stock Sees Improved Relative Strength Rating
In a welcome move, Broadcom stock saw its Relative Strength Rating improve from 70 to 79 on Monday. See if Broadcom stock can continue to show renewed price strength and clear that threshold. Is Broadcom Stock A Buy?
What Awaits These 4 Biotech Stocks That More Than Doubled in 2025
IONS, GPCR, MNPR and KOD more than double in 2025 as policy clarity, M&A revival and clinical wins lift biotech momentum into 2026.
Is Monopar Therapeutics Inc. (NASDAQ:MNPR) Trading At A 46% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Monopar Therapeutics fair value estimate is US$168 Monopar...
Coinbase upgraded, Six Flags downgraded: Wall Street's top analyst calls
Coinbase upgraded, Six Flags downgraded: Wall Street's top analyst calls